Supramolecular dual substrate activation: synthetic methods via coencapsulation

Ended Project Grant Awarded Last action

Award ID
F32GM153093
Recipient
Awarding agency
Obligated
$435,620

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Place of performance
California, USA

Award details come from USAspending.gov.

Description

Abstract
Pharmaceutical technologies are inherently limited by the synthetic methods available to medicinal chemists. Novel transformations in organic chemistry have the potential to enhance human well-being through the prevention of human suffering through pharmaceutical therapies. Modern innovations in synthesis have shown the ability to furnish new molecular scaffolds, especially through the employment of catalytic methods. Past efforts in supramolecular catalysis have offered strategies to more traditional methods by enabling orthogonal selectivity through non-covalent interactions which are imparted via encapsulation. In this way, supramolecular hosts behave similarly to enzymes, inspiring further study due to the allure of the rate enhancements offered by nature's catalysts. Utilizing supramolecular hosts pioneered by the raymond, bergman, and toste groups, we plan to enable several transformations relevant to the production of pharmaceuticals. Previous work with these privileged clusters has shown powerful reactivity through the coencapsulation of two reagents within the host cavity. Trends in these reactions have shown the ability to enhance the electrophilicity of electrophiles through protonation and increased reactivity from nucleophiles through p-p stacking interactions. These motifs will be leveraged for various pharmaceutically relevant transformations, including n-heterocycle reduction and functionalization, regio- and diasteroselective olefin epoxidation. Through the combination of supramolecular catalysis and PT catalysis we also hope to provide methods for an enantioselective c(SP3)-h oxidation of alkanes. These methods all involve the use of widely available or readily synthesized reagents that may be rapidly constructed into valuable pharmacores for use in drug discovery investigations with the ultimate goal of improving human health. The specific aims in this proposal provide a detailed plan for the production of these potent technologies. Under the tutelage of professors toste, bergman, and raymond i will develop these methods with expert guidance in asymmetric reactivity, physical organic chemistry, and organometallic cluster synthesis. Conducting this research at the university of california berkeley provides an optimal environment for both the success of this project and for my personal and professional development as a researcher. Providing the tutelage of brilliant faculty, ambitious colleagues, and stunning state-of-the-art facilities, berkeley offers no limit to the resources for the practicing scientist.

Transactions

Action Obligated Date
Amendment $1,236
Amendment $74,284
Amendment $74,284
Amendment $4,748
Amendment $4,748
Amendment $69,080
Amendment $69,080
Amendment $0
Amendment $0
Amendment $69,080
Amendment $0
Original award $69,080
Show all 12

Quick answers

Who received award F32GM153093?

F32GM153093 was awarded to The Regents Of The University Of California by National Institute of General Medical Sciences (National Institutes of Health) on July 8, 2024.

How much is award F32GM153093 worth?

$435,620 has been obligated on F32GM153093.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award